Skip to content
Menu
About Us
Company Overview
Management
Board of Directors
Our Science
Overview of Assets
Science
Pipeline
Clinical Trials
Expanded Access Policy
Newsroom
Press Releases
Events & Presentations
Investor Relations
Corporate Governance
Financial Information
Annual Reports & Proxy Statements
Investor Contact Info
Contact
Close Menu
Press Releases
January 25, 2024
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
Exceeding Anticipated Timelines with Accelerated Momentum
Interim Data Analysis Anticipated in Mid-2024
Expects Full Enrollment by Q1 2025
View/download press release »
Sign up to receive press releases via email
Leave this field empty if you're human:
